Concurrent thrombotic thrombocytopenic purpura and antiphospholipid syndrome: a rare and severe clinical combination

Díaz-Cremades, Juan; Fernández‐Fuertes, Fernando; Ruano, J. A.; Tapia, Manuel; Soler, Santiago Roquer; Bosch, J. M.; Caballero, Mar; Miguel, José D. González‐San

doi:10.1111/j.1365-2141.2009.07856.x

Cited by 7 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After the above symptomatic treatment (consultation in each department, which included experts in rheumatism and immunity), the symptoms were obviously relieved. Previous reports have shown that TTP presents with antiphospholipid antibody syndrome [12,13], and Pan Yan et al [9] reported that anti-phospholipid antibody syndrome may be the reason for RESLES. Hence, whether RESLES is two associated nodes to be further proved about the author's point of view.…”

Section: Anti-cardiolipin Antibody (Igg + M + A)mentioning

confidence: 99%

Thrombotic thrombocytopenic purpura with reversible splenial lesion syndrome: a case report

Hou

Liu

et al. 2020

BMC Neurol

View full text Add to dashboard Cite

Background: Reversible splenial lesion syndrome (RESLES) is known to cause severe psychiatric symptoms but is also a very rare clinical disease in which the specific aetiology is unknown. According to current reports, there are major causes of the disease, including viral or bacterial infection, epilepsy, anti-epileptic drug withdrawal, highaltitude cerebral oedema, and metabolic disorders such as hypoglycaemia and hypernatraemia. In this article, we report a patient with thrombotic thrombocytopenic purpura (TTP) who presented with RESLES. Case presentation: A 34-year-old female patient who presented with fever and progression of disorder of consciousness was eventually diagnosed with RESLES based on brain imaging. Moreover, clinical features and peripheral smears demonstrating schistocytes and thrombocytopenia confirmed a diagnosis of TTP. RESLES can be improved by plasma exchange therapy. Conclusion: This rare case highlights the occurrence of RESLES as a presenting feature of the expanding list of unusual neurological manifestations of TTP.

show abstract

Section: Anti-cardiolipin Antibody (Igg + M + A)mentioning

confidence: 99%

Thrombotic thrombocytopenic purpura with reversible splenial lesion syndrome: a case report

Hou

Liu

et al. 2020

BMC Neurol

View full text Add to dashboard Cite

show abstract

“…Antiphospholipid syndrome, especially its rare clinical manifestation called catastrophic antiphospholipid syndrome, can make a differential diagnosis with TTP difficult because this clinical form of antiphospholipid syndrome presents with multi-organ failure due to thrombosis and also with thrombocytopenia and microangiopathic anaemia (39). Occasionally, heparin induced thrombocytopenia (HIT) can mimic TTP because of the organ failure due to thrombosis and consequent thrombocytopenia, but a normal platelet count before the initiation of heparin therapy in HIT and confirmation of the antibodies against the complex of heparin and platelet factor 4 distinguish those two disorders (40).…”

Section: Differential Diagnosis Of Ttpmentioning

confidence: 99%

Thrombotic Thrombocytopenic Purpura: Etiopathogenesis, Diagnostics and Basic Principles of Treatment

Todorović

Petrović

et al. 2017

Serbian Journal of Experimental and Clinical Research

View full text Add to dashboard Cite

Th rombotic thrombocytopenic purpura (TTP) is a clinical syndrome that manifests with thrombocytopenia, microangiopathic haemolytic anaemia and symptoms and signs of kidney and brain damage, but it rarely involves other organs. Th e main pathophysiological cause of TTP is diminished metalloproteinase ADAMTS13 activity; the main function of ADAMTS13 is to degrade large multimers of the von SAŽETAK Trombotična trombocitopenijska purpura (TTP) je klinički sindrom koji se odlikuje trombocitopenijom, mikroangiopatskom hemoliznom anemijom i simptomima i znacima oštećenja bubrega i mozga, ređe drugih organa. Glavni patofi ziološki mehanizam nastanka TTP-a je smanjena aktivnost metaloproteinaze ADAMTS13 čija je osnovna uloga razgradnja velikih multimera von Willebrand-ovog faktora. Smanjena aktivnost metaloproteinaze ADAMTS13 nastaje usled mutacije u genu za ADAMTS13 (urođeni TTP) ili usled nastanka antitela koja blokiraju ili antitela koja ubrzavaju razgradnju ADAMTS13 (stečeni TTP

show abstract

“…The unusual case of thrombotic thrombocytopenic purpura (TTP) in association with antiphospholipid syndrome (APS) reported by Díaz‐Cremades et al (2009) present several important considerations in the management of both these disorders. Firstly, the clinical presentation reported emphasises the need for ‘two‐hits’ for the development of clinical features in APS, especially the thrombotic episodes (Levine et al , 2002).…”

mentioning

confidence: 99%

“…In summary, the report by Díaz‐Cremades et al (2009) of the rare association of TTP and APS is interesting, although it is difficult to ascertain whether TTP can occur with APS or whether the clinical and laboratory features of TTP in a patient with APS are secondary to the effect of antiphospholipid antibodies.…”

mentioning

confidence: 99%

The difficult distinction between antiphospholipid syndrome and thrombotic thrombocytopenic purpura

Thachil

2010

Br J Haematol

View full text Add to dashboard Cite

Concurrent thrombotic thrombocytopenic purpura and antiphospholipid syndrome: a rare and severe clinical combination

Cited by 7 publications

References 9 publications

Thrombotic thrombocytopenic purpura with reversible splenial lesion syndrome: a case report

Thrombotic thrombocytopenic purpura with reversible splenial lesion syndrome: a case report

Thrombotic Thrombocytopenic Purpura: Etiopathogenesis, Diagnostics and Basic Principles of Treatment

The difficult distinction between antiphospholipid syndrome and thrombotic thrombocytopenic purpura

Contact Info

Product

Resources

About